Search Videos and More
News
SRS with Immunotherapy Extends Survival in RCC with Brain Metastasis
According to Manmeet Ahluwalia, MD, MBA, FASCO, kidney cancer currently ranks as the fourth most common cancer to metastasize to the brain after lung cancer, breast cancer, and melanoma.
News
Minesh P. Mehta, MD, on NSCLC: Tumor Treating Fields for Brain Metastases
Minesh P. Mehta, MD, of Miami Cancer Institute, part of Baptist Health South Florida, discusses results from the METIS (EF-25) trial evaluating the efficacy and safety of tumor treating fields therapy following stereotactic radiosurgery in patients with mutation-negative non–small cell lung cancer (NSCLC) and brain metastases.
Podcast
Miami Cancer Institute 2024 ASCO Recap
Join Dr. Michael Zinner, CEO and Executive Medical Director of Baptist Health Miami Cancer Institute, and Dr. Manmeet Ahluwalia, Chief of Medical Oncology, Chief Scientific Officer & Deputy Director, and Fernandez Family Endowed Chair in Cancer Research at Baptist Health Miami Cancer Institute, as they highlight the groundbreaking research
News
Novel Stereotactic Radiosurgery Technology Zaps Brain Tumors
Using a novel stereotactic radiosurgery technology, experts at Miami Neuroscience Institute and Miami Cancer Institute, both part of Baptist Health, now have another option to treat patients with a variety of brain tumors and disorders painlessly and without cutting through the skull
News
Minesh Mehta, M.D., Presenting METIS Trial Results at ASCO
The results of the METIS trial will be discussed by renowned radiation oncologist Minesh Mehta, M.D., at the annual meeting of the American Society of Clinical Oncology (ASCO), May 31-June 4, in Chicago.
News
Miami Cancer Institute Brain Metastases and Glioblastoma Research Coming Out of ASCO
The latest results from a number of brain metastasis clinical trials led by physician-investigators at Miami Cancer Institute, part of Baptist Health, are being presented at the annual meeting of the American Society of Clinical Oncology (ASCO), May 31-June 4, in Chicago.
News
Latest Advances in ADC Therapies for Breast Cancer Highlighted at ASCO
Physician-investigators at Miami Cancer Institute, part of Baptist Health, are preparing to launch a new breast cancer clinical trial that will provide critical information regarding the sequential use of antibody drug conjugates (ADCs) in patients with metastatic breast cancer.
News
Clinical Trials at Miami Cancer Institute Investigate Novel Approaches for Treating Blood Cancers
A new clinical trial awaiting final preparations at Miami Cancer Institute, part of Baptist Health, will test premanufactured blood products that researchers hope will lead to “off the shelf” solutions for some patients who require chimeric antigen-specific T-cell therapy to treat their blood cancers.
News
Blood and Marrow Transplantation Program Achieves Accreditation for APP Fellowship Program
Baptist Health Miami Cancer Institute's Malignant Hematology/Blood and Bone Marrow Transplant Fellowship has earned accreditation with distinction as an Advanced Practice Provider Fellowship Program by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation in Practice Transition Programs.
News
Dr. Mehta on the Advantages of MRI-Guided Adaptive Radiotherapy in Cancer Care
Minesh Mehta, M.D., chief of radiation oncology and deputy director of Baptist Health Miami Cancer Institute , discusses the potential utility of radiotherapy, including how the introduction of MRI-guided adaptive radiation therapy systems is improving precision and outcomes across cancer care.
News
Integrated Oncology Research Explores New Pathways for Treatment of Primary and Metastatic Brain Cancer
At Baptist Health Miami Cancer Institute, parallel lines of research are underway to develop transformative approaches to maximize tumor control while protecting neurocognitive function during brain tumor treatment.
News
2024 Caring for Kids with Cancer Symposium
This symposium will provide an update on the latest developments in the management of sarcomas and leukemias including immunotherapy and CAR T-cell therapy.